Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brexanolone · 1 trial · 2 indications
The number and proportion of individuals experiencing any adverse event, any SAE, and any related adverse event overall will be summarized using frequency tables. No formal statistical tests will be conducted, rather the safety will be evaluated from a risk/benefit perspective. Any p-values reported will be for descriptive purposes only.
The change in heart rate a physiological safety/stress measure are continuous and obtained multiple times after study drug administration which occurs on day 1. This measure will be analyzed using descriptive statistics and graphical summaries including time-specific summary statistics (e.g., box and whisker plots).
The change in blood pressure a physiological safety/stress measure are continuous and obtained multiple times after study drug administration which occurs on day 2. This measure will be analyzed using descriptive statistics and graphical summaries including time-specific summary statistics (e.g., box and whisker plots).
The change in Cortisol a physiological safety/stress measure are continuous and obtained multiple times after study drug administration which occurs on day 2. This measure will be analyzed using descriptive statistics and graphical summaries including time-specific summary statistics (e.g., box and whisker plots).
A set of dose-response models will be tested response using the Multiple Comparisons Procedure Modifications (MCP-Mod) methodology including change in percentage of milliliters consumed during the 2-hour ad-libitum drinking paradigm within laboratory sessions (stress and neutral) as dependent variable, the treatment as factor (90, 60, 30 and 0 mcg/kg/h), and baseline dependent value. These dose-response models with repeated measures will be used to test the effects of the regimens of 90, 60, and 30 mcg/kg/h doses of brexanolone on alcohol consumption in self-administration.
Another set of dose-response models will test Multiple Comparisons Procedure Modifications (MCP-Mod) methodology for the 30-day follow-up in PCL-5 score as dependent variable, the treatment as factor (90, 60, 30 and 0 mcg/kg/h), and baseline dependent value. These dose-response models will be used to test the effects of the regimens of 90, 60, 30 and 0 mcg/kg/h doses of brexanolone on PTSD symptoms. Scale PCL-5 is 0-4 with 0 being not at all and 4 being extreme; the higher score is worse outcome
Another set of dose-response models will test Multiple Comparisons Procedure Modifications (MCP-Mod) methodology including change from intake to end of dosing in PCL-5 score as dependent variable, the treatment as factor (90, 60, 30 and 0 mcg/kg/h), and baseline dependent value. The same modeling will be repeated for the 30-day follow-up timepoint. These dose-response models will be used to test the effects of the regimens of 90, 60, 30 and 0 mcg/kg/h doses of brexanolone on PTSD symptoms. Scale PCL-5 is 0-4 with 0 being not at all and 4 being extreme; the higher score is worse outcome
| Arm | Type | Description |
|---|---|---|
| Placebo | NO_INTERVENTION | A 0.9% bag of sodium chloride will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking. |
| 90mcg/kg/h dose of Brexanolone | ACTIVE_COMPARATOR | Brexanolone will be diluted with sterile water and 0.9% sodium chloride and will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking. |
| 60mcg/kg/h dose of Brexanolone | ACTIVE_COMPARATOR | Brexanolone will be diluted with sterile water and 0.9% sodium chloride and will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking. |
| 30mcg/kg/h dose of Brexanolone | ACTIVE_COMPARATOR | Brexanolone will be diluted with sterile water and 0.9% sodium chloride and will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking. |
| Name | Type | Description |
|---|---|---|
| Brexanolone | DRUG | The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion. |
Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female, aged 21-70 years old, either active duty or with a history of US military service. 4. Current DSM-...
Brexanolone is a small-molecule drug being studied by Sage Therapeutics for Alcohol Use Disorder. It acts as a positive allosteric modulator at GABA-A receptor subunits including GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, and GABRG3. It is investigational and is in Phase 2 clinical development for this indication.
Brexanolone is being developed for Alcohol Use Disorder, a psychiatry indication. A Phase 2 study is also evaluating it in veterans with concurrent Alcohol Use Disorder and Post Traumatic Stress Disorder. It has not been established as a treatment outside of clinical research.
Brexanolone targets GABA-A receptor subunits, specifically GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, and GABRG3. It is classified as a positive allosteric modulator, meaning it enhances GABA-A receptor activity. This mechanism underlies its investigation in Alcohol Use Disorder.
Brexanolone is being developed by Sage Therapeutics, Inc., which trades under the ticker SAGE. Sage is the sponsor of the clinical program evaluating brexanolone in Alcohol Use Disorder and related psychiatric conditions.
Brexanolone is in Phase 2 clinical development for Alcohol Use Disorder. It is investigational and has not completed a pivotal program for this indication. The current Phase 2 study is active but not yet recruiting participants.
Brexanolone is being studied in trial NCT06580444, a Phase 2 dose-finding study in veterans with concurrent Alcohol Use Disorder and Post Traumatic Stress Disorder. The trial is randomized, double-blind, and active-controlled, with an planned enrollment of 40 participants aged 21 and older.